Bleximenib with venetoclax and azacitidine in AML

STUDY OVERVIEW:

- This very early stage study (phase IB) tested different doses of **bleximenib**, a menin inhibitor with **venetoclax + azacitidine** in people with **acute myeloid leukemia (AML)**
- **Menin inhibitors** are a new type of treatment for AML. They block a protein called menin, which helps certain leukemia cells grow. This slows or **stops cancer growth**

Who participated?

- **125 people** with AML
- Average age **67 years**

- **40** newly diagnosed
- **85** previously treated

How effective was the treatment?

The most effective daily dose was:

100 mg twice daily

No signs of cancer in the blood or bone marrow were observed after treatment (complete remission):

Newly diagnosed



Previously treated

What were the most common side effects?

Most common side effects with 100 mg dose:

65% felt sick

61% had low platelets (thrombocytopenia)

49% had low red blood cells (anemia)

3 cases of changes to heart rhythm

2 cases of differentiation syndrome*

WHAT DOES THIS MEAN FOR PEOPLE WITH AML?

- AML is associated with the lowest survival among leukemias. However, 3 in 4 patients with newly diagnosed AML, and over half of patients with previously treated AML, achieved complete remission in response to bleximenib with venetoclax and azacitidine
- Side effects were consistent with what was expected for venetoclax and azacitidine together
- This treatment is now moving to the **next stage of testing** in a larger phase III trial (called cAMeLot-2) for people with newly diagnosed AML who can't have intensive chemotherapy

** **Note:** Differentiation syndrome is a side effect linked to treatments like menin inhibitors, which cause leukemia cells to mature quickly. It can be serious, but is treatable if caught early.*

References: *Wei, A et al. Presentation at the European Hematology Association 2025 Congress, Milan, June, 2025. Abstract s137.*
The Leukemia & Lymphoma Society. Facts 2022-2023: Updated data on blood cancers. https://www.lls.org/sites/default/files/2023-08/PS80_Facts_2022_2023.pdf. Accessed: July 2025.

ALAN
Acute Leukemia Advocates Network